학술논문
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
Document Type
Article
Author
de Botton, S.; Fenaux, P.; Yee, K.; Récher, C.; Wei, A.H.; Montesinos, P.; Taussig, D.C.; Pigneux, A.; Braun, T.; Curti, A.; Grove, C.; Jonas, B.A.; Khwaja, A.; Legrand, O.; Peterlin, P.; Arnan, M.; Blum, W.; Cilloni, D.; Hiwase, D.K.; Jurcic, J.G.; Krauter, J.; Thomas, X.; Watts, J.M.; Yang, J.; Polyanskaya, O.; Brevard, J.; Sweeney, J.; Barrett, E.; Cortes, J.
Source
In: Blood Advances . (Blood Advances, 11 July 2023, 7(13):3117-3127)
Subject
Language
English
ISSN
24739537
24739529
24739529